The phase III trial, XT-XTR008-3-01, was a randomised controlled trial (RCT) that evaluated the efficacy and safety of XTR008, a novel no-carrier-added lutetium-177 (177Lu)–Dotatate, for the first time in a later-line therapy setting for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of all origins.
177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial☆
Annals of Oncology | | J. Xu, J. Chen, S. Song, L. Song, R. Wang, J. Hao, X. Du, D. Cao, Y. Gao, X. Lan, A. Yang, W. Miao, H. Xu, Y. Chen, L. Li, H. Shi, X. Yuan, F. Ye, J. Wang, N. Xu, X. Han, X. Li, R. Huang, T. Zhang, E. Li, R. Wang, Y. Zhou, H. Chen, X. Zhu, J. Zhao, X. Su, Y. Cui, P. Ren, P. Wang
Topics: pancreatic-cancer, blood-cancer, clinical-trials, research